Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

Anti-PD-1 (anti-programmed cell death 1) and anti-PD-L1 (anti-programmed cell death ligand 1) regimens are preferred therapies for many cancers, including cancers associated with HIV. However, patients with HIV were excluded from most registered trials.The primary objective was to evaluate the safet...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Thomas S. Uldrick, Priscila Gonçalves, Maher Abdul‐Hay, Alisa J Claeys, Brinda Emu, Marc S. Ernstoff, Steven P. Fling, Lawrence Fong, Judith C. Kaiser, Andreanne M. Lacroix, Steve Y. Lee, Lisa Lundgren, Kathryn Lurain, Christopher Parsons, Sharavi Peeramsetti, Ramya Ramaswami, Elad Sharon, Mario Sznol, Chia-Ching Wang, Robert Yarchoan, Martin A. Cheever
Formatua: Artigo
Hizkuntza:ingelesa
Argitaratua: 2019
Sarrera elektronikoa:https://doi.org/10.1001/jamaoncol.2019.2244
https://jamanetwork.com/journals/jamaoncology/articlepdf/2735517/jamaoncology_uldrick_2019_oi_190054.pdf
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

https://doi.org/10.1001/jamaoncol.2019.2244
https://jamanetwork.com/journals/jamaoncology/articlepdf/2735517/jamaoncology_uldrick_2019_oi_190054.pdf

Antzeko izenburuak